Skip to main content
Toggle navigation
Login
Search
Home
Tweets by 2022 IKCS: Europe
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Like
Tweet this
Print
Robert J. Motzer, MD
Memorial Sloan Kettering Cancer Center, United States of America
Poster(s):
22: Characterization and Management of Adverse Reactions in Patients With Advanced Renal Cell Carcinoma Receiving Lenvatinib + Pembrolizumab (CLEAR Study)
29: LITESPARK-011: Belzutifan Plus Lenvatinib Versus Cabozantinib: A Randomized, Open-Label Phase 3 Study in Patients With Advanced Renal Cell Carcinoma (RCC) After Anti–PD-1/PD-L1 Therapy